Mandate

Vinge advises Actic Group AB (publ) in connection with its listing on Nasdaq Stockholm

Vinge has advised Actic Group AB (publ) (”Actic”) in connection with its listing on Nasdaq Stockholm. The prospectus was published on 28 March 2017 and the first day of trading on Nasdaq Stockholm was 7 April 2017.

The offer price was SEK 50.50 per share, corresponding to a market value for Actic of approximately SEK 800 million. The offer related to 8 613 860 shares, of which 5 346 534 were newly issued shares and 3 267 326 were existing shares which were offered by the selling shareholder Actic International S.à r.l., which is owned by IK 2007 Fund. The total value of the offer amounted to approximately SEK 500 million on the assumption that the oversubscription option is exercised in full.

Actic is a North European operator of health care facilities focusing on Sweden, Norway and Germany, and with a presence in Finland and Austria. As per 31 December 2016, Actic had approximately 211 000 members divided into 166 facilities in five countries with approximately 700 employees. During 2016, Actic’s total revenues amounted to approximately SEK 800 million. The company was formed in 1981 and its head office is situated in Solna.

Vinge’s team primarily consisted of Jonas Bergström, Jesper Schönbeck, David Andersson, Joel Wahlberg, Annika Nyberg Ekenberg and Christian Brelin. Linda Sengul, Johanna Wiberg and Marith Welin Berger provided advice regarding due diligence. Louise Brorsson Salomon, Helena Håkansson and Adam Sandberg provided advice relating to financing issues.

Related

Vinge has advised Vimian Group AB in connection with its uplisting to Nasdaq Stockholm

Vinge has advised Vimian Group AB (publ) in connection with its list change from Nasdaq First North Growth Market to Nasdaq Stockholm’s main market, Large cap. The prospectus was published on 21 March 2025 and the trading on Nasdaq Stockholm commenced on 28 March 2025.
March 28, 2025

Vinge advises Tribune Therapeutics in conjunction with financing round

Vinge advises Tribune Therapeutics, a Swedish biotechnology company focused on developing therapies for fibrotic diseases, in raising 23 MEUR. The financing round includes the previous investors HealthCap, Novo Holding and Innovestor, in addition to the new investors LifeArc Ventures, Industrifonden and Investinor.
March 26, 2025

Vinge advises Dignitana on the public offer from Paxman

Paxman AB (publ) has announced a public offer to the shareholders of Dignitana AB. The total value of the offer is approximately SEK 153 million.
March 24, 2025